Research and Forecast of Microvascular Complications of Diabetes in France Industry 2016 to 2022
Researchmoz added Most up-to-date research on "PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022" to its huge collection of research reports.
(EMAILWIRE.COM, January 04, 2017 )
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
The 2012 base-year market sales of products for MCD in France were around $153m. As in the global market, this growth will be fueled by the dramatic increase in prevalence and diagnosis, as well as by the uptake of new branded drugs, such as atrasentan and Optina. The uptake of drugs receiving additional approval for the treatment of diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further boost sales in the MCD market.
Scope
Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in France from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the France MCD market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186887
Table of Content
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Diabetic Nephropathy 16
3.1.2 Diabetic Retinopathy 18
3.1.3 Diabetic Neuropathy 19
3.2 Prognosis 20
3.3 Quality of Life 21
3.4 Symptoms 22
4 Disease Management 23
4.1 Treatment Overview 23
4.1.1 Diagnosis and Referrals 23
4.1.2 Screening 25
4.1.3 Treatment Guidelines 26
4.2 France 33
4.2.1 Diagnosis 33
4.2.2 Clinical Practice 35
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
The 2012 base-year market sales of products for MCD in France were around $153m. As in the global market, this growth will be fueled by the dramatic increase in prevalence and diagnosis, as well as by the uptake of new branded drugs, such as atrasentan and Optina. The uptake of drugs receiving additional approval for the treatment of diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further boost sales in the MCD market.
Scope
Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in France from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the France MCD market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186887
Table of Content
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Diabetic Nephropathy 16
3.1.2 Diabetic Retinopathy 18
3.1.3 Diabetic Neuropathy 19
3.2 Prognosis 20
3.3 Quality of Life 21
3.4 Symptoms 22
4 Disease Management 23
4.1 Treatment Overview 23
4.1.1 Diagnosis and Referrals 23
4.1.2 Screening 25
4.1.3 Treatment Guidelines 26
4.2 France 33
4.2.1 Diagnosis 33
4.2.2 Clinical Practice 35
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Contact Information:
Researchmoz Global Pvt.Ltd
Researchmoz
Tel: +1-518-621-2074
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Researchmoz Global Pvt.Ltd
Researchmoz
Tel: +1-518-621-2074
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results